Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on ...
Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...
Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the Nasdaq MarketSite in Times Square as part of the company’s 50th anniversary ...
Shares of Bio-Techne Corp. advanced 5.19% to $57.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 6,890.07 and the ...
MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31 ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
What Happened? A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the ...
Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...
Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...